Dapagliflozin Presented Nonalcoholic Fatty Liver Through Metabolite Extraction and AMPK/NLRP3 Signaling Pathway
Horm Metab Res DOI: 10.1055/a-1970-3388In recent years, the incidence rate of nonalcoholic fatty liver disease (NAFLD)
has been increasing year by year. The experiments conducted on rat elucidated
the effect and underlying mechanism of dapagliflozin in NAFLD. Sprague Dawley
rats were fed with HFD (Fat accounts for 52%, carbohydrate 34%
and protein 14%) for 12 weeks as NAFLD model. Dapagliflozin presented
NAFLD in rat model. Dapagliflozin reduced oxidative stress and inflammation in
rat model of NAFLD. Dapagliflozin reduced oxidative stress and inflammation in
vitro model of NAFLD. Dapagliflozin in a model of NAFLD metabolized into
histamine H1 receptor, caffeine metabolism, mannose type O-glycan biosynthesis,
choline metabolism in cancer, tryptophan metabolism, and glycerophospholipid
metabolism. Dapagliflozin induced AMPK/NLRP3 signaling pathway. The
regulation of AMPK/NLRP3 signaling pathway affected the effects of
dapagliflozin on nonalcoholic fatty liver. In summary, dapagliflozin plays a
preventative role in NAFLD through metabolite extraction, the inhibition of
oxidative stress, and inflammation by AMPK/NLRP3 signaling pathway.
Dapagliflozin may be a potential therapeutic agent for oxidative stress and
inflammation in model of NAFLD. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Lin, Deng Song, Yuling Tags: Original Article: Endocrine Research Source Type: research